Integra LifeSciences Holdings (IART) 2012年年度报告「NASDAQ」.pdf

1、LIMITING UNCERTAINTY IS HOW WE MAKE A DIFFERENCE.Integra 2012 Annual ReportTotal RevenuesSelected Financial Data:2012 Revenues by Geographic AreaUnited StatesEuropeRest of World2012 Revenues by SegmentSegment%of Total Revenues Key Product Areas 2012 RevenuesU.S.NeurosurgeryU.S.InstrumentsU.S.Extremi

2、tiesU.S.Spine&OtherInternational21%19%15%23%22%Dural repair,ultrasonic aspiration,cranial stabilization,stereotaxy,neuro critical careGeneral and specialty hand-held surgical instruments in the hospital and office-based settings;surgical headlights and retractorsSoft tissue repair for nerve,tendon,s

3、kin and wound;fixation and joint replacement in foot,ankle,hand,wrist,elbow and shoulderMIS spine system,traditional spine fusion,orthobiologics,private label*Select product lines from each of Neurosurgery,Instruments,Extremities and Spine$171 Million$162 Million$123 Million$191 Million$184 MillionC

4、ompany at a GlanceRegion2012 Revenues$643 Million$691 Million$697 MillionOperating Cash FlowDiluted Earnings Per ShareIn 2012,we generated$58.7 million in cash flows from operations,which was reduced by a$29.8 million tax withholding payment in connection with the release of certain deferred stock u

5、nits and$30.6 million of accreted interest paid at the maturity of our 2012 Senior Convertible Note.*World leader in medical technology,with a focus on regenerative medicine Founded in 1989 and headquartered in Plainsboro,NJ Offers innovative solutions in orthopedic extremity surgery,neurosurgery,sp

6、ine surgery,and reconstructive and general surgery Employs approximately 3,500 people worldwide Sells through direct reps in the U.S.,Canada,major European markets and Australia,and through distributors in these and over 100 countriesTo our Stockholders:In 2012,we made significant progress against a